SF Client Bioptigen Closes $1.5M Equity Financing

RESEARCH TRIANGLE PARK — Bioptigen Inc. has closed its first securities offering in four years, selling $1.5 million of equity to a single investor, according to an SEC filing. The financing was completed with the advisory support of Scale Finance’s Tom Livingston serving as Bioptigen’s CFO.

Bioptigen, which was spun off in August 2004 from Duke University‘s Biomedical Engineering Department, has developed a class of in vivo optical imaging systems that it says enables real-time, noninvasive imaging of internal tissue microstructure. The systems also can be used in drug development, genetics research, tissue engineering and medical vision, Bioptigen says.

The technology came from the laboratories of Professor Joseph Izatt, who now serves as the company’s chairman and chief technology officer.

Principals named in the current Reg D filing are Bioptigen President and CEO Eric Buckland and CFO Thomas Livingston.

This was Bioptigen’s first fund-raising since a $542,500 sale of mixed securities in 2007, according to an SEC filing at the time.